Oral semaglutide is approved for marketing in China Oral semaglutide tablets are a new type of hypoglycemic ** drug, which is a glucagon-like peptide-1 (GLP-1) receptor agonist, which can mimic the body's own GLP-1, regulate blood sugar levels, suppress appetite, and delay gastric emptying, so as to achieve the purpose of weight control and diabetes. The advantage of oral semaglutide tablets is that it avoids the inconvenience and pain of injections, only needs to be taken once a day, and does not need to be refrigerated. Its hypoglycemic and ** effects are also more significant than other GLP-1 drugs, and clinical trials have shown that it can reduce HbA1C levels in patients with type 2 diabetes by 1More than 5%, and more than 15% weight loss.
At present, this drug has been approved for marketing in 29 countries around the world, including the United States, the European Union, Japan, Australia, etc. In the United States, the drug is marketed under the trade name Rybelsus, with a box of 30 tablets of 7 mg each, and costs about $800 USD, which is equivalent to about 5,200 yuan. In Japan, the drug is known as Ruibeishi, with a box of 28 tablets of 7 mg each, and costs about $400 USD, which is equivalent to about 2,600 yuan. In the European Union, the trade name of this drug is ozempic, and it costs about $600 euros per box of 7 mg per box of 30 tablets, which is equivalent to about 4,700 yuan.
Due to the high ** of this drug, many patients may want to buy it online, but this is very discouraged. Because the drugs on the Internet may be counterfeit, or expired, or adulterated with other ingredients, these may cause serious harm to the health of patients. In addition, this medication is not something that can be taken casually, it needs to be adjusted according to the patient's specific situation under the guidance of a doctor to achieve the best results.
On January 26, according to the information on the official website of the State Food and Drug Administration, Novo Nordisk's semaglutide tablets (trade name: Novo Xin) were approved for marketing for **type 2 diabetes**. At that time, patients can buy this drug at a regular hospital or pharmacy with a doctor's prescription.
Oral semaglutide tablets are an innovative hypoglycemic drug that provides a new option for patients with type 2 diabetes, but it is not a panacea, and patients also need to cooperate with diet control and exercise to achieve the best results.
If you want to know more about this drug, welcome to follow my medical science account, I will share more medical knowledge and the latest research for you.